Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan in HER2+ or HER2-low advanced breast cancer with brain metastases
NCT04420598Phase 2Completed
- Sponsor
- MEDSIR
- Start
- May 2020
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by MEDSIR. Primary endpoints: Progression-Free Survival at 16 weeks, Objective Response Rate at 16 months and 1 more. Started May 2020; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04420598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420598.